Figure 1.
An overview of the two trials, the periods with missing OPV, and the periods with ongoing subgroup studies in Guinea-Bissau 2004.
Figure 2.
PPD stimulated IFN-γ (A), IL-5 (B), IL-13 (C), TNF-α (D) and IL-10 (E) production in low birth weight BCG (LBW BCG) and BCG+OPV vaccinated (LBW BCG+OPV) infants.
One dot represents one individual. Horizontal lines represent medians.
Figure 3.
PPD stimulated IFN-γ (A), IL-5 (B), IL-13 (C), TNF-α (D) and IL-10 (E) production in normal birth weight BCG (NBW BCG) and BCG+OPV vaccinated (NBW BCG+OPV) infants.
One dot represents one individual. Horizontal lines represent medians.
Table 1.
Description of the cytokine study population.
Table 2.
Description of the scar and PPD study population.
Table 3.
Comparison of the frequency of cytokine responders in children vaccinated with BCG and with BCG+OPV.
Table 4.
The effect of receiving OPV with BCG at birth on the likelihood of having an in vivo response to PPD at age 2 months and 6 months.
Table 5.
The effect of receiving OPV with BCG at birth on the likelihood of being scar positive at age 2 and 6 months.
Figure 4.
Comparison of BCG scar size at age 2 months between infants who got or did not get OPV with BCG at birth.